Platinum Investment Management’s Arcus Biosciences RCUS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $4.14M | Hold |
134,217
| – | – | 1.02% | 35 |
|
|
2026
Q1 | $2.9M | Hold |
134,217
| – | – | 0.73% | 50 |
|
|
2025
Q4 | $3.2M | Sell |
134,217
-19,566
| -13% | -$399K | 0.74% | 52 |
|
|
2025
Q3 | $2.09M | Hold |
153,783
| – | – | 0.14% | 66 |
|
|
2025
Q2 | $1.25M | Hold |
153,783
| – | – | 0.08% | 70 |
|
|
2025
Q1 | $1.21M | Hold |
153,783
| – | – | 0.07% | 68 |
|
|
2024
Q4 | $2.29M | Hold |
153,783
| – | – | 0.13% | 58 |
|
|
2024
Q3 | $2.35M | Hold |
153,783
| – | – | 0.11% | 63 |
|
|
2024
Q2 | $2.34M | Sell |
153,783
-50,615
| -25% | -$817K | 0.09% | 61 |
|
|
2024
Q1 | $3.86M | Hold |
204,398
| – | – | 0.16% | 49 |
|
|
2023
Q4 | $3.9M | Hold |
204,398
| – | – | 0.16% | 59 |
|
|
2023
Q3 | $3.67M | Sell |
204,398
-28,214
| -12% | -$567K | 0.14% | 57 |
|
|
2023
Q2 | $4.72M | Hold |
232,612
| – | – | 0.16% | 57 |
|
|
2023
Q1 | $4.24M | Buy |
232,612
+77,761
| +50% | +$1.49M | 0.15% | 61 |
|
|
2022
Q4 | $3.2M | Buy |
154,851
+93,071
| +151% | +$2.56M | 0.12% | 65 |
|
|
2022
Q3 | $1.62M | Hold |
61,780
| – | – | 0.07% | 84 |
|
|
2022
Q2 | $1.57M | Hold |
61,780
| – | – | 0.06% | 91 |
|
|
2022
Q1 | $1.95M | Hold |
61,780
| – | – | 0.06% | 85 |
|
|
2021
Q4 | $2.5M | Hold |
61,780
| – | – | 0.07% | 88 |
|
|
2021
Q3 | $2.15M | Sell |
61,780
-13,510
| -18% | -$420K | 0.06% | 98 |
|
|
2021
Q2 | $2.07M | Hold |
75,290
| – | – | 0.05% | 92 |
|
|
2021
Q1 | $2.11M | Sell |
75,290
-11,768
| -14% | -$410K | 0.05% | 86 |
|
|
2020
Q4 | $2.26M | Hold |
87,058
| – | – | 0.05% | 88 |
|
|
2020
Q3 | $1.49M | Hold |
87,058
| – | – | 0.04% | 91 |
|
|
2020
Q2 | $2.15M | Sell |
87,058
-16,682
| -16% | -$450K | 0.05% | 82 |
|
|
2020
Q1 | $1.44M | Hold |
103,740
| – | – | 0.04% | 84 |
|
|
2019
Q4 | $1.05M | Sell |
103,740
-33,153
| -24% | -$279K | 0.02% | 85 |
|
|
2019
Q3 | $1.25M | Sell |
136,893
-9,300
| -6% | -$74.7K | 0.03% | 78 |
|
|
2019
Q2 | $1.16M | Hold |
146,193
| – | – | 0.03% | 81 |
|
|
2019
Q1 | $1.83M | Hold |
146,193
| – | – | 0.04% | 69 |
|
|
2018
Q4 | $1.57M | Buy |
146,193
+50,352
| +53% | +$588K | 0.05% | 59 |
|
|
2018
Q3 | $1.34M | Buy |
95,841
+43,000
| +81% | +$548K | 0.04% | 65 |
|
|
2018
Q2 | $647K | Buy |
52,841
+42,841
| +428% | +$672K | 0.02% | 81 |
|
|
2018
Q1 | $154K | Buy |
+10,000
| New | +$167K | ﹤0.01% | 85 |
|
Other funds holding RCUS
GS
SCM
WP
Platinum Investment Management's RCUS Position: Q2 2026 in Review
Platinum Investment Management held its Arcus Biosciences (RCUS) position steady in Q2 2026 at 134,217 shares worth $4.14M. The position accounts for 1.02% of the portfolio, ranked #35.
Platinum Investment Management first reported a position in RCUS in Q1 2018 and has held it in 34 quarters since. The position peaked at $4.72M in Q2 2023. 231 funds tracked by Wall St. Rank hold RCUS as of Q2 2026.
- Platinum Investment Management held 134,217 shares of Arcus Biosciences worth $4.14M as of Q2 2026.
- Platinum Investment Management left its Arcus Biosciences share count unchanged in Q2 2026.
- Arcus Biosciences made up 1.02% of Platinum Investment Management's portfolio in Q2 2026, its #35 holding.
- Platinum Investment Management first reported a position in Arcus Biosciences in Q1 2018 and has held it in 34 quarters since.
- Platinum Investment Management's Arcus Biosciences position peaked at $4.72M in Q2 2023.
- 231 funds tracked by Wall St. Rank held Arcus Biosciences as of Q2 2026.
Based on Platinum Investment Management's 13F filing for Q2 2026, filed 13 Aug 2026.